Investigation of Genetic Determinants of Capecitabine Toxicity.

Trial Profile

Investigation of Genetic Determinants of Capecitabine Toxicity.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Jul 2016

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 24 Jul 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.
    • 13 Aug 2012 Planned end date changed from 1 Apr 2012 to 1 Apr 2014 as reported by ClinicalTrials.gov.
    • 18 Jul 2012 New source identified and integrated (Mayo Clinic).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top